Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05328102
Title Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Xencor, Inc.
Age Groups: adult | senior
Covered Countries USA | FRA | ESP

No variant requirements are available.